Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/92831
Type: | Conference item |
Title: | The adverse effect of high sokal risk for first line imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatment |
Author: | Branford, S. Yeung, D. Ross, D. Parker, W. Braley, J. Seymour, J. Hughes, T. |
Citation: | Blood, 2014, vol.124, iss.21, pp.816-816 |
Publisher: | American Society of Hematology |
Issue Date: | 2014 |
ISSN: | 0006-4971 1528-0020 |
Conference Name: | 56th ASH Annual Meeting (6 Dec 2014 - 9 Dec 2014 : San Francisco, California) |
Statement of Responsibility: | Susan Branford, David T Yeung, David M Ross, Wendy T Parker, Jodi Braley, John F Seymour, and Timothy P. Hughes |
Rights: | © 2014 by The American Society of Hematology |
Appears in Collections: | Aurora harvest 7 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.